



Par Pharmaceutical
300 Tice Blvd, Suite 230
Woodcliff Lake, NJ 07677

www.parpharm.com

May 24, 2023

AGO.highcostprescriptiondrugs@vermont.gov

Notice of a New Prescription Drug Pursuant to 18 V.S.A. § 4637(b)

Dear Office of the Vermont Attorney General,

Par Pharmaceutical, Inc. ("Par") is issuing this notice pursuant to 18 V.S.A. § 4637(b), which asks prescription drug manufacturers to provide the Office of the Attorney General (the "Office") written notice within three calendar days of releasing a drug in the commercial market whose wholesale acquisition cost ("WAC") exceeds the threshold set for a specialty drug under the Medicare Part D Program.

On May 24, 2023, Par informed potential customers the following drug product was available for order:

NDC #	Product Description
10370-0365-11	Topiramate ER Caps 25mg 30s
10370-0365-01	Topiramate ER Caps 25mg 100s
10370-0367-11	Topiramate ER Caps 100mg 30s
10370-0367-01	Topiramate ER Caps 100mg 100s

On or about May 24, 2023, Par intends to commence shipping the aforementioned drug product to its third party customers.

The WAC for the drug product identified above exceeds the threshold set for a specialty drug under the Medicare Part D Program. Please note that the WAC-related information provided in this notice may be subject to change.

In the event Vermont S. 92 and the laws it implements, including 18 V.S.A. § 4637, are found invalid, Par reserves all of its legal rights. In issuing this notice in an attempt to comply with 18 V.S.A. § 4637, Par does not waive any legal claims or legal rights related to potential constitutional defects with Vermont S. 92.

Sincerely,

Scott Sims, SVP & GM Injectable Solutions and Generics
Par Pharmaceutical an endo company